Mineralys Therapeutics, Inc.
NASDAQ:MLYS · NASDAQ Global Select
+$0.37 today
Vol 3.33M · Avg 1.48M
Filings
Ground the analysis in primary documents
Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.
Price History
Dividend-adjusted closing price
Change
+78.87%
Period High
$47.33
Period Low
$12.87
Latest
$24.63
SEC Filings
Recent regulatory filings
No filings found.
Competitors
Peer companies in the same sector
Cidara Therapeutics, Inc.
CDTX
$5.61B
Scholar Rock Holding Corporation
NASDAQ:SRRK
$5.56B
Apellis Pharmaceuticals, Inc.
APLS
$5.25B
Catalyst Pharmaceuticals, Inc.
NASDAQ:CPRX
$3.84B
Beam Therapeutics Inc.
NASDAQ:BEAM
$3.40B
IDEAYA Biosciences, Inc.
NASDAQ:IDYA
$2.92B
Adaptive Biotechnologies Corporation
NASDAQ:ADPT
$2.78B
Zai Lab Limited
NASDAQ:ZLAB
$2.06B
Agios Pharmaceuticals, Inc.
NASDAQ:AGIO
$2.00B
Recursion Pharmaceuticals, Inc.
NASDAQ:RXRX
$1.42B
What is the latest MLYS filing?
The latest filing shown is 4 dated Jun 17, 2026.
How many recent filings does MLYS have?
Intrinsic Alpha currently shows 20 recent filings for MLYS.
Explore More
Continue the stock analysis
Jump to another research area for this company.